Journal
HEMATOLOGICAL ONCOLOGY
Volume 37, Issue -, Pages 70-74Publisher
WILEY
DOI: 10.1002/hon.2587
Keywords
-
Categories
Funding
- NATIONAL CANCER INSTITUTE [ZIABC011914] Funding Source: NIH RePORTER
Ask authors/readers for more resources
ctDNA provides an important new strategy that will aid in the treatment of non-Hodgkin's lymphoma. Immunoglobulin sequencing provides a tumor specific marker for disease activity with a sensitivity equivalent to one tumor cell per 10-6. Furthermore, it can provide an estimate of tumor bulk and tumor response dynamics during treatment. Interim monitoring can identify patients at high risk of treatment failure and surveillance monitoring can identify patients months before radiographic disease progression. Tumor specific mutations can also be detected in ctDNA and may reflect an averaging of mutations present within multiple tumor masses. Such analysis may aid in the molecular characterization of tumors and selection of targeted treatments for precision medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available